A Multicentric, Retrospective Efficacy and Safety Study of Nanosomal Docetaxel Lipid Suspension in Metastatic Castration-Resistant Prostate Cancer

Table 2

Treatment delivery.

Treatment	2-weekly NDLS (N = 9)	3-weekly NDLS (N = 15)
Cumulative dose (mg), median (range)	650 (240–1660)	500 (300–750)
No. of cycles, median (range)	14 (6–40)	10 (6–11)
Actual dose intensity (mg/m^2/week), median (range)	21.04 (20–37.50)	18.75 (16.67–25)
Relative dose intensity (%), median (range)	84 (80–150)	75 (67–100)

Calculated at a planned dose intensity of 25 mg/m²/week.